The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: Evidence from the CLEAR study

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 120-123

  Kiberd, Bryce A ^a   Wrobel, Michelle ^b   Dandavino, Raymond ^c   Keown, Paul ^d   Gourishankar, Sita ^e  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b Hoffmann La Roche Ltd   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

kidney transplantation; mycophenolic acid; proton pump inhibitors; therapeutic drug monitoring

Indexed keywords

ALBUMIN; CREATININE; ESOMEPRAZOLE; LANSOPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PANTOPRAZOLE; PREDNISONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS;

ADULT; ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CREATININE BLOOD LEVEL; DRUG EXPOSURE; HUMAN; INTENTION TO TREAT ANALYSIS; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; CREATININE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PREDNISONE; PROTON PUMP INHIBITORS; TACROLIMUS;

EID: 78751642276     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318206a1b1     Document Type: Article

References (16)

1. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997;63:39-47.
2. Anreoni KA, Brayman KL, Guidinger MK, et al. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant. 2007;7: 1359-1375.
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmaokinet. 2007;46:13-58.
4. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68: 261-266.
5. Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: a 5-day 3-g loading dose of mycophenolate mofetil versus standard 2-3 dosing in renal transplantation. Clin J Am Soc Nephrol. 2010;5:1282-1289.
6. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
7. Kofler S, Deutsch M-A, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28:605-611.
8. Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients - a prospective case-controlled study. Am J Transplant. 2009;9:1650-1656.
9. Rupprecht K, Schmidt C, Raspé A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol. 2009;49:1196-1201.
10. Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30:46-51.
11. Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology 2010;49:2061-2067.
12. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety. 2006;29:769-784.
13. van Gelder T, Pescovitz M, Elzein H, et al. The effect of gastric pH modulators on the pharmacokinetics of mycophenolate mofetil (MMF) in de novo renal transplant patients. Presented at the International Congress of the Transplantation Society 2004 [Abstract].
14. Fan PYW, Barraclough KA, Isbel NM, et al. Impact of omeprazole on mycophenolic acid pharmacokinetics in adult kidney transplant recipients. Presented at the International Congress of the Transplantation Society 2010 [Abstract #P13.18].
15. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.
16. van Gelder T, Tedesco Silva H, de Fijter JW, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation. 2010;89:595-599.